|
|
|||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Tue., Jun. 18, 7:38 PM
|
||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #5 of 25 |
Slide #5. Valeant Pharmaceuticals International, Inc. — Secondary Offering
Company:
Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
Date announced:
6/17/2013
Secondary Offering Details:
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has filed a preliminary prospectus supplement to its effective shelf registration statement on Form S-3 and has today made a similar filing with securities regulatory authorities in each of the provinces of Canada in connection with a public offering of its common shares to raise gross proceeds of approximately $1.75 billion (the "Offering").
Valeant Pharmaceuticals International is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Co.'s specialty pharmaceutical and over-the-counter (OTC) products are marketed under brand names across the U.S., Canada, Australia and New Zealand. Co. also has branded generic, branded, and OTC operations in Europe, Latin America, South East Asia and South Africa. As of Dec 31 2011, Co.'s product portfolio comprises of 900 products, with about 4,100 stock keeping units. Co.'s segments are: U.S. Neurology and Other; U.S. Dermatology; Canada and Australia; Branded Generics — Europe; and Branded Generics — Latin America.
Open the VRX Page at The Online Investor »
|
|||||||||||||||||||||
Open the VRX Page at The Online Investor (in a new window) »
|
Trade VRX Now: |
Avg. Broker Rec.
 
|
Buy (3.23 out of 4) 66th percentile
(ranked higher than approx. 66% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2013, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.